Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of remibrutinib in chronic spontaneous urticaria
2019-001074-29Phase 2Unknown
- Sponsor
- Novartis
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of remibrutinib in chronic idiopathic urticaria (CIU), sponsored by Novartis. Primary endpoint: Treatment-emergent adverse events (serious and non-serious). Status: unknown.
02
Drugs
remibrutinib
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2019-001074-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001074-29.